Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.44 |
| ▸ | RXRA | P19793 | 6/20 | 0.43 |
| ▸ | RXRB | P28702 | 6/20 | 0.43 |
| ▸ | RXRG | P48443 | 6/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883873 | 0.90 | PTGDR2 (0.49) | PTGDR2NR3C1RXRARXRBRXRG | |
| SCHEMBL2067362 | 0.89 | NR3C1 (0.50) | PTGDR2NR3C1KCNQ3KCNQ2RXRA | |
| SCHEMBL883824 | 0.88 | PTGDR2 (0.55) | PTGDR2KCNQ3KCNQ2RXRARXRB | |
| SCHEMBL2065914 | 0.88 | PTGDR2 (0.49) | PTGDR2NR3C1RXRARXRBRXRG | |
| SCHEMBL585822 | 0.86 | KCNQ3 (0.41) | PTGDR2NR3C1KCNQ3KCNQ2 | |
| SCHEMBL585259 | 0.83 | KCNQ3 (0.41) | PTGDR2NR3C1KCNQ3KCNQ2 | |
| SCHEMBL4766658 | 0.81 | KCNQ3 (0.40) | PTGDR2KCNQ3KCNQ2PTGS2 | |
| SCHEMBL585444 | 0.81 | RORC (0.44) | PTGDR2 | |
| SCHEMBL883847 | 0.80 | PTGDR2 (0.48) | PTGDR2RXRARXRBRXRGTHRB | |
| SCHEMBL2066397 | 0.79 | RXRA (0.46) | PTGDR2NR3C1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963259-B1 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1963259-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | AstraZeneca AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068894-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | PNMT, SQOR, SMS | PTGDR2 120/4885NR3C1 523/4885KCNQ3 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.